News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 1, 2022 Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
May 12, 2022 Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2022 Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
May 4, 2022 Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022 Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
May 2, 2022 Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
April 26, 2022 Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
April 21, 2022 Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
April 4, 2022 Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference